Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Heron Therapeutics Inc. HRTX

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:HRTX)

Fundamentals Snapshot (NDAQ:HRTX)

Current News (NDAQ:HRTX)

Heron Therapeutics Announces $76.5 Million Private Placement Financing

PR Newswire 9 days ago

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates

PR Newswire 9 days ago

Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

PR Newswire August 2, 2022

Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability

PR Newswire June 30, 2022

Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty

PR Newswire June 14, 2022

Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference

PR Newswire May 26, 2022

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

PR Newswire May 26, 2022

Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting

PR Newswire May 16, 2022

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates

PR Newswire May 9, 2022

Opinion & Analysis (NDAQ:HRTX)

No current opinion is available.

Bullboard Posts (NDAQ:HRTX)